LYRA: Lyra Therapeutics Company Aggregate Debts

Symbol and logo of brand Lyra Therapeutics Inc. (LYRA)

High competition from generics and industry behemoths is putting pressure on share prices. The debt timeline visualizes this market risk, where 0.00 reflects the latest metric value. Stability is supported by the brand's impeccable image within the scientific community and the innovative LYR-210 system, which replaces surgery for the treatment of chronic sinusitis, expanding the reach within the ENT market for Lyra Therapeutics, Inc. (LYRA).

LYRA: Lyra Therapeutics, Inc. Company Debts 07/04/2022 - 03/28/2026

Lyra Therapeutics (LYRA) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart Lyra Therapeutics Inc|LYRA - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Lyra Therapeutics, Inc|LYRA - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Lyra Therapeutics|LYRA - Company Book Value|Market Cap to Net Assets Ratio lyratherapeutics.com|LYRA - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Lyra Therapeutics, Inc.|LYRA - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Lyra Therapeutics Inc.|LYRA - Company Debts|Debts to Book Value Lyra Therapeutics, Inc|LYRA - Company Long-Term Liabilities|Amount of Current Liabilities Lyra Therapeutics|Intermediate Coverage Ratio lyratherapeutics.com
- earnings and valuation multiples information:
LYRA - Net Profit
Fundamental company analysis:LYRA - Lyra Therapeutics Inc
Signature product of Lyra Therapeutics Inc.

The success of the innovative drug delivery platform Lyra Therapeutics, Inc. (LYRA) depends directly on its ability to fund risky Phase 3 trials without incurring a critical debt load. An analysis of total debt allows for an assessment of the balance between leveraging borrowed capital and the risk of default, where rising liabilities in the absence of revenue signals declining financial stability and a potential drawdown in share prices.

Who Lyra Therapeutics, Inc. competes with

HLN (Haleon Corp) - Aggregate Debt Obligations|Company Aggregate Debts KVUE (Kenvue Inc.)|Company Aggregate Debts veronapharma.com VRNA|MENS - Company Debts|Aggregate Debt Obligations LGND (Ligand Pharmaceuticals Incorporated)|Amneal Pharmaceuticals Inc (AMRX) - Company Debts|Company Total Debt Perrigo Corp|ALVO (Alvotech) - Company Aggregate Debts|Company Aggregate Debts liquidia.com|Company Total Debt GLPG (Galapagos)|ANIP (ANI Pharmaceuticals Inc) - Aggregate Debt Obligations|Company Debts MannKind Corp. MNKD|Amphastar Corp (AMPH) - Company Cumulative Debt|PCRX: Company Total Debt|ars-pharma.com - Company Cumulative Indebtedness|TBPH: Company Aggregate Debts|Aquestive Therapeutics Inc - Aggregate Debt Obligations|SCPH (scPharmaceuticals, Inc.) - Company Aggregate Debts|Company Cumulative Debt Tectonic TECX|Company Debts Tonix Pharmaceuticals (TNXP)|SXTC (sxtchina.com) - Aggregate Debt Obligations|Company Debts Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences, Inc. - Company Debts|EXOZ: Company Total Debt|Company Cumulative Debt Oramed Pharmaceuticals|enterabio.com (ENTX) - Company Debts|ipatherapeutics.com - Aggregate Debt Obligations|ABVC (ABVC BioPharma, Inc.) - Company Aggregate Debts|Company Aggregate Debts Cumberland Pharmaceuticals Inc|Company Total Debt QNTM (Quantum BioPharma Limited)|FGEN (FibroGen Corporation) - Aggregate Debt Obligations|Telomir Pharmaceuticals - Company Total Debt|Company Cumulative Indebtedness RANI (Rani Therapeutics Holdings)|Synergy CHC Corporation - Company Aggregate Debts|Aggregate Debt Obligations RLYB (Rallybio Corporation)|LEXX: Company Aggregate Debts|Company Cumulative Debt Pulmatrix Corporation (PULM)|Company Debts Pheton Holdings Limited|APM: Aggregate Debt Obligations|Company Aggregate Debts IBO|Company Aggregate Debts tnfpharma.com (TNFA)|Company Debts cbdMD YCBD|PRFX (PainReform Corp) - Company Aggregate Indebtedness|Auris Medical - Company Aggregate Debts|Company Cumulative Debt lipella.com|OPTN (OptiNose) - Company Total Debt|Pieris Pharmaceuticals Inc (PIRS) - Company Aggregate Debts|Company Total Debt PROC|PTPI (Petros Pharma) - Company Cumulative Indebtedness|Company Aggregate Debts QLI|Company Total Debt Obligations acelyrin.com|Company Aggregate Debts TFFP (TFF Pharmaceuticals, Inc.)